What fixed‑dose inhaler combinations (brand and generic names) are available for chronic obstructive pulmonary disease treatment in India, and what are their recommended dosing regimens?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Fixed-Dose Inhaler Combinations for COPD Treatment in India

Available Triple Therapy Combinations

India was the first country to approve fixed-dose triple combination therapy for COPD, with beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY) being the pioneering triple inhaler approved in the Indian market 1.

Currently available fixed-dose triple combinations (ICS/LAMA/LABA) in India include:

  • Beclomethasone dipropionate/Formoterol fumarate/Glycopyrronium bromide (BDP/FOR/GLY) - extrafine formulation that demonstrated reduced exacerbation risk, improved lung function, and favorable health status compared to dual therapy 2, 3

  • Fluticasone furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) - showed protective effects against COPD exacerbations with improved lung function outcomes 3, 4

  • Budesonide/Glycopyrronium bromide/Formoterol fumarate (BUD/GLY/FOR) - demonstrated comparable efficacy to other triple combinations in reducing exacerbations and improving lung function 3, 4

Dual Bronchodilator Combinations (LABA/LAMA)

For patients with moderate-to-high symptom burden (CAT ≥10, mMRC ≥2) and FEV1 <80%, dual bronchodilator therapy (LABA/LAMA) represents the preferred initial approach before escalating to triple therapy 5, 6.

Available LABA/LAMA combinations include:

  • Indacaterol/Glycopyrronium - 24-hour acting combination with superior exacerbation prevention compared to 12-hour LABAs 7

  • Formoterol/Glycopyrronium - available in multiple formulations 2

  • Vilanterol/Umeclidinium - once-daily combination 2

  • Olodaterol/Tiotropium - 24-hour bronchodilation 7

ICS/LABA Dual Combinations

ICS/LABA combinations should be reserved specifically for patients with asthma-COPD overlap, as they increase pneumonia risk without clear benefit in pure COPD patients without exacerbation history 5, 6.

Available ICS/LABA combinations:

  • Beclomethasone dipropionate/Formoterol 2

  • Fluticasone furoate/Vilanterol 2

  • Budesonide/Formoterol 3

Recommended Dosing Regimens by Clinical Scenario

For Low Symptom Burden (Group A: CAT <10, mMRC 0-1, FEV1 ≥80%)

  • Start with single long-acting bronchodilator (LAMA or LAMA) once daily, with LAMA slightly preferred for superior exacerbation prevention 5, 6

  • All patients should have short-acting bronchodilator available as needed for breakthrough symptoms 5

For High Symptoms, Low Exacerbation Risk (Group B: CAT ≥10, mMRC ≥2, FEV1 <80%, <2 exacerbations/year)

  • Initiate LABA/LAMA dual bronchodilator therapy once daily as first-line treatment 5, 6

  • If persistent breathlessness on monotherapy, escalate from single agent to LABA/LAMA combination 5

For High Exacerbation Risk (Group D: ≥2 moderate or ≥1 severe exacerbation/year)

  • Single-inhaler triple therapy (LAMA/LABA/ICS) once daily is strongly recommended as it reduces mortality with moderate certainty of evidence 5, 6

  • Triple therapy dosing: BDP/FOR/GLY 87/5/9 mcg two inhalations twice daily, or FF/UMEC/VI 100/62.5/25 mcg one inhalation once daily, or BUD/GLY/FOR 320/18/9.6 mcg two inhalations twice daily 2, 3, 4

Blood Eosinophil-Guided Escalation Strategy

For patients with eosinophils <100 cells/μL on LABA/LAMA experiencing exacerbations, do not escalate to triple therapy; instead add oral therapies (azithromycin or roflumilast) 5.

For patients with eosinophils ≥300 cells/μL on LABA/LAMA who develop exacerbations, escalate to triple therapy (LABA/LAMA/ICS) 5, 6.

Special Considerations for Indian Population

The Indian COPD population has unique characteristics including high burden of exacerbating disease, significant nonsmoker COPD prevalence, and frequent asthma-COPD overlap, which may necessitate earlier optimization to single-inhaler triple therapy compared to Western populations 8.

Key factors supporting early triple therapy in India:

  • High prevalence of biomass fuel exposure causing COPD in nonsmokers 8

  • Overlapping asthma-COPD phenotypes requiring ICS component 8

  • Poor adherence to multiple inhaler regimens, making single-inhaler triple therapy advantageous 8

Critical Pitfalls to Avoid

  • Never use ICS monotherapy in COPD as it increases pneumonia risk without exacerbation benefit 5, 6

  • Do not prescribe ICS-containing regimens to low-risk patients without documented exacerbation history 5

  • Avoid prescribing multiple devices with different inhalation techniques, which increases exacerbations and medication errors 5

  • In high-risk exacerbators, starting with dual therapy and waiting for further exacerbations delays the mortality benefit of triple therapy 5

  • Monitor for increased pneumonia risk with ICS-containing regimens, particularly in patients with eosinophils <100 cells/μL 5, 6

References

1
Research

Bifunctional Drugs for the Treatment of Respiratory Diseases.

Handbook of experimental pharmacology, 2017

2
Research

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

International journal of chronic obstructive pulmonary disease, 2018

5
Guideline

COPD Management Guideline Update

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

Initiating or Continuing Long-Acting Bronchodilators in COPD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended dose of Breztri (budesonide, glycopyrrolate, formoterol) for severe Chronic Obstructive Pulmonary Disease (COPD)?
What is the preferred initial treatment between budesonide (corticosteroid) and Berodual (ipratropium and fenoterol) for a Chronic Obstructive Pulmonary Disease (COPD) patient?
What is a good Long-Acting Muscarinic Antagonist (LAMA) inhaler in the UK for Chronic Obstructive Pulmonary Disease (COPD) management, including dosage?
What is the next inhaler option for a patient with Chronic Obstructive Pulmonary Disease (COPD) who is not responding to Trelegy Ellipta (fluticasone/fumeclidine/vilanterol)?
What is the best treatment option for stable Chronic Obstructive Pulmonary Disease (COPD), Breztri (budesonide, glycopyrrolate, and formoterol) or Breo (fluticasone furoate and vilanterol)?
How should I urgently manage stool impaction in an elderly, immobile patient with chronic constipation who is taking constipating medications such as opioids, anticholinergics, calcium‑channel blockers, or iron supplements?
What is thyrotoxic periodic paralysis and what is the appropriate treatment for a young adult Asian male with hyperthyroidism?
How do I evaluate a child with edema to determine if it is pitting or non‑pitting, and what are the likely causes and initial management?
For a patient with a low‑grade fever (<38 °C), what initial work‑up is recommended and why are blood cultures performed only when the temperature reaches ≥38 °C or there are signs of systemic infection?
What is the appropriate colistin (colistimethate sodium) dosing regimen for an adult, including loading dose, maintenance dose, renal function adjustments, and inhaled adjunct for ventilator‑associated pneumonia?
What is the lowest blood pressure at which metoprolol 12.5 mg can be safely initiated or continued in an adult without severe heart‑failure decompensation, bradycardia, or acute coronary ischemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.